Results 21 to 30 of about 22,312 (181)
Invasive candidiasis in children
The prevalence of invasive candidiasis (IC) in pediatric hospitals is from 4,3 to 15,2 per 10,000 hospitalized, in ICU – from 3,5 to 7 cases per 1,000, with HSCT – 2,9%. The average length of stay of a patient in the hospital before the development of IC
N. N. Klimko, O. P. Kozlova
doaj +1 more source
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Nathan P Wiederhold1, Jason M Cota2, Christopher R Frei11University of Texas at Austin College of Pharmacy, Austin, Texas, USA; 2University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USAAbstract: Micafungin is an echinocandin ...
Nathan P Wiederhold +2 more
doaj +4 more sources
Diagnosing Invasive Candidiasis [PDF]
ABSTRACT Cultures are negative in ∼50% of invasive candidiasis. Data are emerging for the performance of nonculture tests such as mannan/antimannan, Candida albicans germ tube antibody, 1,3-β- d -glucan, PCR, and the T2Candida panel in diagnosing both candidemia and deep-seated ...
Cornelius J, Clancy, M Hong, Nguyen
openaire +2 more sources
Microbiota-driven interleukin-17 production provides immune protection against invasive candidiasis
Background The intestinal microbiota plays a crucial role in human health, which could affect host immunity and the susceptibility to infectious diseases.
Mengmeng Li +6 more
doaj +1 more source
Clinical periodontal diagnosis
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi +5 more
wiley +1 more source
Pathogenesis of invasive candidiasis
Disseminated candidiasis remains a life-threatening disease in the ICU. The development of invasive disease with Candida albicans is dependent on multiple factors, such as colonization and efficient host defense at the mucosa. In the present review, we describe the host defense mechanisms against Candida that are responsible for counteracting mucosal ...
Veerdonk, F.L. van de +2 more
openaire +3 more sources
Echinocandins in invasive candidiasis
SummaryWe summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managingIC. The echinocandins have demonstrated good activity against non‐albicansinfections and also azole‐resistant strains, both preclinically and in recent clinical trials.
Simon, J. +13 more
openaire +3 more sources
Vaccines in the treatment of invasive candidiasis [PDF]
Candida albicans is the most common cause of hematogenously disseminated candidiasis, and this disease is particularly prevalent in immunocompromised patients. The mortality of invasive candidiasis remains 40% to 50% even with the proper treatment with current antifungal drugs.
Wang, Xiao-juan +5 more
openaire +2 more sources
Immunotherapy and Antifungal Drugs of Candidiasis: Achievements and Challenges
Candida albicans is the most common cause of invasive candidiasis, but in recent years the incidence of infections caused by other species such as Candida Kruzei, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida lusitania has ...
leili Aghebati-Maleki +3 more
doaj
Background The occurrence of invasive fungal infections in COVID-19 patients is on surge in countries like India. Several reports related to rhino-nasal-sinus mucormycosis in COVID patients have been published in recent times; however, very less has been
Roopak Dubey +5 more
doaj +1 more source

